March 31, 2025

Considerations for the accelerated acceptance of new approach methodologies (NAMs) and in-vitro alternatives for product testing and development

Biopharma, chemical and other companies seeking to develop new products or compounds face the challenge of navigating complex animal research regulations and routine ethical considerations. Many are opting for innovations in conducting research that replaces or reduces animal use while still meeting regulatory requirements and ensuring product safety
March 31, 2025

Cell and Gene Therapy Answers: Understanding gene editing and its possible applications

Your source for answers to the complex challenges of cell and gene therapy development.Gene editing offers new possibilities for treating genetic diseases, enhancing immunotherapies, strengthening immune systems and more. To learn more about this cutting-edge technology, including key considerations, emerging opportunities and its potential to transform healthcare, we spoke to NingChun Liu, enterprise director for cell and gene therapy at Labcorp. 
January 30, 2025

Fully automated extraction of high-quality total nucleic acids from FFPE specimens for comprehensive genomic profiling of solid tumors

Abstract: Comprehensive Genomic Profiling (CGP) has emerged as a progressive standard of care for the understandingclinical oncology and treatment of solid tumors (Conroy, Pabla et al. 2021). By identifying actionable mutationsthrough next-generation sequencing of solid tumors CGP enables targeted therapy decisions. Formalin-fixedparaffin-embedded tissues are notoriously difficult samples in respect to reliably extracting high-qualitynucleic acids and sufficient genetic material to meet sequencing input requirements. In this work we presentan automated solution for upstream sample processing of solid tumors to enable high throughput and scalableCGP workflows by eliminating bottlenecks and enhancing results. The Sonication STAR automated DNA and RNAmethods from FFPE Tissues was created as a collaboration between Hamilton Company, Covaris, and Labcorpand it offers the potential reduction in quantity not sufficient (QNS) samples and sequencing performance improvementsresulting in a 16 % increase in fully reported tumor profiles for patients. This automated approachoffers potential saving in workflow costs, improved efficiency, and a reduction in re-extraction and re-sequencingof tumors.